Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Trump considers tax hike on Americans making $2.5...
GOP senators: Congress should vote on Trump’s potential...
White House highlights over $2B in savings from...
GOP talk on millionaire tax hike ‘makes no...
Trump’s first vice president urges his old boss...
Department of Justice opens criminal investigation into NY...
Trump claims ‘I don’t know her’ and ‘listened...
Rubio just got an additional job in Trump’s...
OpenAI’s Sam Altman thanks Sen John Fetterman for...
Former Supreme Court Justice David Souter dead at...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

Soaring Medicare prescription drug prices targeted in Trump’s new executive order

by admin April 16, 2025
April 16, 2025
Soaring Medicare prescription drug prices targeted in Trump’s new executive order

President Donald Trump is seeking to combat soaring prescription drug prices in a new executive order he signed Tuesday. 

The order instructs Robert F. Kennedy Jr.’s Department of Health and Human Services (DHS) to standardize Medicare payments for prescription drugs — including those used for cancer patients — no matter where a patient receives treatment. This could lower prices for patients by as much as 60%, according to a White House fact sheet.

Likewise, the order also calls to match the Medicare payment for certain prescription drugs to the price that hospitals pay for those drugs — up to 35% lower than what the government pays to acquire those medications, the White House said. 

The order also takes steps to lower insulin prices. Specifically, the order calls for lowering insulin prices for low-income patients or those that are uninsured to as little as three cents, and injectable epinephrine to treat allergic reactions to as low as $15, coupled with a ‘small administrative fee,’ according to a White House fact sheet. 

Additionally, the order attempts to drive down states’ drug prices by ‘facilitating importation programs that could save states millions in prescription drug prices,’ as well as bolstering programs that assist states secure deals on sickle-cell medications in Medicaid, the fact sheet said. 

The order also requires DHS to seek comment on the Medicare Drug Price Negotiation Program, which the Biden administration authorized under the Inflation Reduction Act and allows Medicare to directly engage in hashing out prescription prices with drug companies. 

‘The guidance shall improve the transparency of the Medicare Drug Price Negotiation Program, prioritize the selection of prescription drugs with high costs to the Medicare program, and minimize any negative impacts of the maximum fair price on pharmaceutical innovation within the United States,’ the order said. 

Drug prices have significantly ramped up in recent years. Between January 2022 and January 2023, prescription drug prices rose more than 15% and reached an average of $590 per drug product, according to the Department of Health and Human Services. Of the 4,200 prescription drugs included on that list, 46% of the price increases exceeded the rate of inflation. 

Previous efforts under the first Trump administration to curb prescription drug prices included installing a cap on Medicaid prescription drug plans for insulin at $35. 

Meanwhile, Trump’s 145% tariffs on Chinese imports to the U.S. could mean that healthcare costs are particularly susceptible to price increases. Market research group Black Book Research found that 84% of experts predict that prices for medical treatments and drugs will rise due to the tariffs, according to a survey released in February. 

Additionally, Trump signaled Monday that tariffs on the pharmaceutical were headed down the pipeline. 

‘We don’t make our own drugs anymore,’ Trump told reporters Monday. ‘The drug companies are in Ireland, and they’re in lots of other places, China.’

Trump signed the executive order Tuesday, along with others that seek to prevent illegal immigrants from accessing Social Security benefits, and another one calling to investigate the impact of imported processed mineral on national security. 

Tuesday’s executive order comes days after the Department of Health and Human Services’ Centers for Medicare and Medicaid Services told states Thursday that the federal government would cease assistance to states to fund nonmedical services geared toward things like nutrition for those enrolled in Medicaid. 

Fox News’ Alec Schemmel contributed to this report. 

This post appeared first on FOX NEWS

previous post
White House quietly floats millionaire tax hike proposal in Congress as GOP leaders signal opposition
next post
Top Hegseth advisor Dan Caldwell placed on administrative leave by Defense Department

You may also like

Congress unveils bill to avert Friday government shutdown...

December 18, 2024

Israel denies entry to two British lawmakers accused...

April 7, 2025

Atlantic reporter publishes more texts about attack on...

March 26, 2025

Obama allies, advisers helped lead the charge among...

July 22, 2024

Rep. Marjorie Taylor Greene airs frustrations, warns that...

May 5, 2025

Trump picks Dr. Marty Makary as Food and...

November 23, 2024

Trump cautions ‘bad things’ in store if Iran...

March 29, 2025

Kamala Harris’ new climate director said she is...

September 10, 2024

Trump-district Democrat warns party ‘in trouble’ ahead of...

March 25, 2025

Hunter Biden pardon raises new questions over 5th...

December 4, 2024

Recent Posts

  • Trump considers tax hike on Americans making $2.5 million or more per year
  • GOP senators: Congress should vote on Trump’s potential Iran nuclear deal
  • White House highlights over $2B in savings from DEI cuts during Trump administration’s first 100 days
  • GOP talk on millionaire tax hike ‘makes no sense,’ Trump White House alum says
  • Trump’s first vice president urges his old boss against raising taxes on wealthy Americans

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (712)
    • Investing (2,058)
    • Politics (2,553)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.